Kancera AB - ESG Rating & Company Profile powered by AI
Jump to the end of the page for potential risks for Kancera AB based on industry, geography and size. This assessment of Kancera AB leverages data points from across the internet and also from public filings by Kancera AB. This ESG score includes seventeen United Nations SDGs including: 'Gender Equality', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'.
Kancera AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Kancera AB | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kancera AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kancera AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Kancera AB report the average age of the workforce?
Sign up for free to unlockDoes Kancera AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kancera AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kancera AB disclose cybersecurity risks?
Sign up for free to unlockDoes Kancera AB offer flexible work?
Sign up for free to unlockDoes Kancera AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kancera AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kancera AB conduct supply chain audits?
Sign up for free to unlockDoes Kancera AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kancera AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kancera AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kancera AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kancera AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kancera AB disclose water use targets?
Sign up for free to unlockDoes Kancera AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Kancera AB have a product recall in the last two years?
Sign up for free to unlockDoes Kancera AB disclose incidents of discrimination?
Sign up for free to unlockDoes Kancera AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kancera AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kancera AB disclose parental leave metrics?
Sign up for free to unlockDoes Kancera AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kancera AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kancera AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kancera AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kancera AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kancera AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kancera AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Kancera AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kancera AB disclose its waste policy?
Sign up for free to unlockDoes Kancera AB report according to TCFD requirements?
Sign up for free to unlockDoes Kancera AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kancera AB disclose energy use targets?
Sign up for free to unlockDoes Kancera AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kancera AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kancera AB
These potential risks are based on the size, segment and geographies of the company.
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.